BIOMAT Database Logo BIOMAT Database Logo

Discovery of novel 7-azaindole derivatives bearing dihydropyridazine moiety as c-Met kinase inhibitors. 2017

Qidong Tang, and Linxiao Wang, and Yongli Duan, and Wenhui Wang, and Shunmin Huang, and Jia Zhi, and Shuang Jia, and Wufu Zhu, and Ping Wang, and Rong Luo, and Pengwu Zheng
School of Pharmacy, Jiangxi Science and Technology Normal University, Nanchang 330013, PR China. Electronic address: tangqidongcn@126.com.

A series of 7-azaindole derivatives bearing the dihydropyridazine scaffold were synthesized and evaluated for their c-Met kinase inhibitory, and antiproliferative activity against 4 cancer cell lines (HT29, A549, H460, U87MG) were evaluated in vitro. Most compounds showed moderate to excellent potency. Compared to foretinib, the most promising analog 34 (c-Met IC50: 1.06 nM, a multitarget tyrosine kinase inhibitor) showed a 6.4-, 7.8-, and 3.2-fold increase in activity against HT29, A549, and H460 cell lines, respectively. Structure activity relationship studies indicated that mono-EWGs (such as R2 = F) at 4-position of moiety D was a key factor in improving the antitumor activity.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011724 Pyridazines Six-membered rings with two adjacent nitrogen atoms also called 1,2-diazine.
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Qidong Tang, and Linxiao Wang, and Yongli Duan, and Wenhui Wang, and Shunmin Huang, and Jia Zhi, and Shuang Jia, and Wufu Zhu, and Ping Wang, and Rong Luo, and Pengwu Zheng
Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-Met kinase inhibitors.
February 2014, Bioorganic & medicinal chemistry,
Qidong Tang, and Linxiao Wang, and Yongli Duan, and Wenhui Wang, and Shunmin Huang, and Jia Zhi, and Shuang Jia, and Wufu Zhu, and Ping Wang, and Rong Luo, and Pengwu Zheng
Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors.
June 2013, Bioorganic & medicinal chemistry,
Qidong Tang, and Linxiao Wang, and Yongli Duan, and Wenhui Wang, and Shunmin Huang, and Jia Zhi, and Shuang Jia, and Wufu Zhu, and Ping Wang, and Rong Luo, and Pengwu Zheng
Discovery of novel quinazoline derivatives bearing semicarbazone moiety as potent EGFR kinase inhibitors.
January 2018, Computational and structural biotechnology journal,
Qidong Tang, and Linxiao Wang, and Yongli Duan, and Wenhui Wang, and Shunmin Huang, and Jia Zhi, and Shuang Jia, and Wufu Zhu, and Ping Wang, and Rong Luo, and Pengwu Zheng
Design and optimization of novel 4-(2-fluorophenoxy)quinoline derivatives bearing a hydrazone moiety as c-Met kinase inhibitors.
November 2014, European journal of medicinal chemistry,
Qidong Tang, and Linxiao Wang, and Yongli Duan, and Wenhui Wang, and Shunmin Huang, and Jia Zhi, and Shuang Jia, and Wufu Zhu, and Ping Wang, and Rong Luo, and Pengwu Zheng
Synthesis and evaluation of 7-azaindole derivatives bearing benzocycloalkanone motifs as protein kinase inhibitors.
June 2020, Bioorganic & medicinal chemistry,
Qidong Tang, and Linxiao Wang, and Yongli Duan, and Wenhui Wang, and Shunmin Huang, and Jia Zhi, and Shuang Jia, and Wufu Zhu, and Ping Wang, and Rong Luo, and Pengwu Zheng
Design and biological evaluation of novel 4-(2-fluorophenoxy)quinoline derivatives bearing an imidazolone moiety as c-Met kinase inhibitors.
August 2015, Bioorganic & medicinal chemistry,
Qidong Tang, and Linxiao Wang, and Yongli Duan, and Wenhui Wang, and Shunmin Huang, and Jia Zhi, and Shuang Jia, and Wufu Zhu, and Ping Wang, and Rong Luo, and Pengwu Zheng
Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel ALK inhibitors.
July 2022, Bioorganic & medicinal chemistry,
Qidong Tang, and Linxiao Wang, and Yongli Duan, and Wenhui Wang, and Shunmin Huang, and Jia Zhi, and Shuang Jia, and Wufu Zhu, and Ping Wang, and Rong Luo, and Pengwu Zheng
Discovery of 2,4-diarylaminopyrimidine derivatives bearing sulfonamide moiety as novel FAK inhibitors.
January 2024, Bioorganic chemistry,
Qidong Tang, and Linxiao Wang, and Yongli Duan, and Wenhui Wang, and Shunmin Huang, and Jia Zhi, and Shuang Jia, and Wufu Zhu, and Ping Wang, and Rong Luo, and Pengwu Zheng
Discovery of substituted pyrazol-4-yl pyridazinone derivatives as novel c-Met kinase inhibitors.
April 2016, Archives of pharmacal research,
Qidong Tang, and Linxiao Wang, and Yongli Duan, and Wenhui Wang, and Shunmin Huang, and Jia Zhi, and Shuang Jia, and Wufu Zhu, and Ping Wang, and Rong Luo, and Pengwu Zheng
Discovery of N-substituted-3-phenyl-1,6-naphthyridinone derivatives bearing quinoline moiety as selective type II c-Met kinase inhibitors against VEGFR-2.
June 2020, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!